Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population
Open Access
- 10 February 2012
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 64 (7) , 1054-1060
Abstract
Objective: To evaluate adherence to drug therapy among new users of zoledronate and intravenous (IV) ibandronate among US Medicare enrollees.Methods: We used data from the Medicare 5% random sample to evaluate new users of IV zoledronate and IV ibandronate with continuous Part A and Part B fee‐for‐service coverage. The outcome was adherence as quantified by the proportion of days covered (PDC) measured continuously and dichotomously (≥80%). Followup time extended from 18–27 months for all individuals. Factors associated with low adherence to zoledronate were evaluated with logistic regression.Results: We identified 775 new users of zoledronate and 846 new users of IV ibandronate. For both drugs, 30–48% of the first infusions were given in an outpatient infusion center, not in a physician's office. The mean PDC for zoledronate users was 82%, which was greater than the mean PDC for the IV ibandronate users (58–62% depending on the time period; P < 0.0001). Approximately 30% of zoledronate users did not receive a second infusion. Factors associated with low adherence to zoledronate included older age and receipt of the first infusion in an outpatient infusion center rather than a physician's office.Conclusion: Less frequently dosed IV bisphosphonates have not resolved the problem of suboptimal adherence with prescription osteoporosis medications. Interventions continue to be warranted to improve long‐term adherence to osteoporosis treatments.Keywords
This publication has 25 references indexed in Scilit:
- C-B4-03: Promoting Adherence to Improve Effectiveness of Cardiovascular Disease Therapies (PATIENT): Implementing a Medication Adherence Intervention Using Health Information TechnologyClinical Medicine & Research, 2011
- Estimating bisphosphonate use and fracture reduction among US women aged 45 years and older, 2001–2008Journal of Bone and Mineral Research, 2010
- At Pitney Bowes, Value-Based Insurance Design Cut Copayments And Increased Drug AdherenceHealth Affairs, 2010
- Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The NetherlandsOsteoporosis International, 2010
- Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature reviewOsteoporosis International, 2009
- A blinded randomized controlled trial of motivational interviewing to improve adherence with osteoporosis medications: design of the OPTIMA trialOsteoporosis International, 2009
- Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and EuropeThe American Journal of Medicine, 2009
- Benefit of Adherence With Bisphosphonates Depends on Age and Fracture Type: Results From an Analysis of 101,038 New Bisphosphonate UsersJournal of Bone and Mineral Research, 2008
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Evaluating Medication Effects Outside of Clinical Trials: New-User DesignsAmerican Journal of Epidemiology, 2003